Education
About Us
Working with TipRanks
Follow Us
Enzon Pharmaceuticals (ENZN)
OTHER OTC:ENZN
Total Valuation
Enzon Pharmaceuticals has a market cap or net worth of $7.35M. The enterprise value is ―.
Market Cap$7.35M
Enterprise Value―
Share Statistics
Enzon Pharmaceuticals has 74,214,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding74,214,600
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Enzon Pharmaceuticals’s return on equity (ROE) is 0.26 and return on invested capital (ROIC) is -2.02%.
Return on Equity (ROE)0.26
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)-2.02%
Return on Capital Employed (ROCE)-0.03
Revenue Per Employee10.00T>
Profits Per Employee10.00T>
Employee Count―
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Enzon Pharmaceuticals is 14.89. Enzon Pharmaceuticals’s PEG ratio is 0.02.
PE Ratio14.89
PS Ratio311.42
PB Ratio3.85
Price to Fair Value3.85
Price to FCF10.33
Price to Operating Cash Flow10.33
PEG Ratio0.02
Income Statement
In the last 12 months, Enzon Pharmaceuticals had revenue of 26.00K and earned 778.00K in profits. Earnings per share was 0.01.
Revenue26.00K
Gross Profit26.00K
Operating Income-1.33M
Pretax Income1.13M
Net Income778.00K
EBITDA-1.33M
Earnings Per Share (EPS)0.01
Cash Flow
In the last 12 months, operating cash flow was 1.12M and capital expenditures 0.00, giving a free cash flow of 1.12M billion.
Operating Cash Flow1.12M
Free Cash Flow1.12M
Free Cash Flow per Share0.02
Dividends & Yields
Enzon Pharmaceuticals pays an annual dividend of $0.119, resulting in a dividend yield of ―
Dividend Per Share$0.119
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change25.00%
50-Day Moving Average0.11
200-Day Moving Average0.13
Relative Strength Index (RSI)47.86
Average Volume (3m)16.99K
Important Dates
Enzon Pharmaceuticals upcoming earnings date is Nov 8, 2023, TBA Not Confirmed.
Last Earnings DateAug 3, 2023
Next Earnings DateNov 8, 2023
Ex-Dividend DateSep 30, 2019
Financial Position
Enzon Pharmaceuticals as a current ratio of 28.10, with Debt / Equity ratio of 0.00%
Current Ratio28.10
Quick Ratio28.10
Debt to Market Cap0.00
Net Debt to EBITDA35.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Enzon Pharmaceuticals has paid 347.00K in taxes.
Income Tax347.00K
Effective Tax Rate0.31
Enterprise Valuation
Enzon Pharmaceuticals EV to EBITDA ratio is 26.58, with an EV/FCF ratio of -31.44.
EV to Sales-1.36K
EV to EBITDA26.58
EV to Free Cash Flow-31.44
EV to Operating Cash Flow-31.44
Balance Sheet
Enzon Pharmaceuticals has $46.86M in cash and marketable securities with $134.50M in debt, giving a net cash position of -$46.86M billion.
Cash & Marketable Securities$46.86M
Total Debt$134.50M
Net Cash-$46.86M
Net Cash Per Share-$0.63
Tangible Book Value Per Share$0.04
Margins
Gross margin is 100.00%, with operating margin of -5103.85%, and net profit margin of 2992.31%.
Gross Margin100.00%
Operating Margin-5103.85%
Pretax Margin4326.92%
Net Profit Margin2992.31%
EBITDA Margin-5103.85%
EBIT Margin-5103.85%
Analyst Forecast
The average price target for Enzon Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―